Centene Stock Surges on Q1 EPS Beat and $6B Revenue Guidance Upgrade
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Centene Corporation (NYSE: CNC) is a Fortune 500 healthcare enterprise headquartered in St. Louis, Missouri. Founded in 1984 as Managed Health Services, Centene specializes in government-sponsored and privately insured programs, including Medicaid, Medicare, the Health Insurance Marketplace, and Tricare. As of 2023, Centene ranked No. 25 on the Fortune 500 list.
Corporate Structure and Workforce
Centene employs 60,300 people as of June 30, 2025, and serves approximately 28 million managed-care members across all 50 states—roughly 1 in 15 individuals nationwide. Operating through locally branded health plans, the company combines centralized functions (finance, risk management, compliance) with community-based teams to tailor services to regional needs. Sarah M. London has served as Chief Executive Officer since March 2022.
Healthcare by Luis Melendez
Recent Developments and News
On April 25, 2025, Centene reported first-quarter results for the period ended March 31, 2025, including:
- Diluted EPS of $2.63 and Adjusted Diluted EPS of $2.90, up 28% from $2.26 in Q1 2024.
- Premium and service revenues of $42.5 billion, a 17% increase year-over-year.
- Membership growth of 29% in the Marketplace line and 22% in the Medicare Prescription Drug Plan line compared to Q1 2024.
- An upward revision of full-year 2025 premium and service revenue guidance by $6.0 billion.
In April 2025, SilverSummit Healthplan was awarded a five-year (plus two-year extension) Medicaid managed-care contract in Nevada. In March 2025, Meridian Health Plan secured a four-year contract in Illinois to continue fully integrated dual eligible special needs services beginning in January 2026. Fortune Magazine recognized Centene as one of “America’s Most Innovative Companies” in March 2025.
Financial and Strategic Analysis
Centene’s trailing twelve-month financial metrics (as of September 11, 2025) illustrate its scale and profitability:
| Metric | Value |
|---|---|
| Revenue (TTM) | $159.56 billion |
| Net Income (TTM) | $2.05 billion |
| Diluted EPS (TTM) | $4.12 |
| Price/Earnings Ratio (TTM) | 7.59 |
| Health Benefits Ratio (Q1 2025) | 87.5% |
| Total Cash (MRQ) | $17.28 billion |
| Debt/Equity Ratio (MRQ) | 63.9% |
| Free Cash Flow (TTM) | $1.54 billion |
Strategically, Centene has reinforced its core businesses through:
- Continued expansion in Medicaid and Marketplace enrollment.
- Divestiture of Magellan Rx and PANTHERx Rare for $2.8 billion in May 2022 as part of a strategy to streamline pharmacy benefit management.
- Local partnerships and community investments, such as grants for housing redevelopment in Atlanta and mobile health services in rural Hawaiʻi.
Market Position and Industry Context
As the largest Medicaid managed-care organization and a significant carrier in the Marketplace, Centene differentiates itself with a local-brand model that addresses unique state and community requirements. Regulatory changes under the Affordable Care Act and state Medicaid redeterminations influence membership and margins. Demographic trends—such as an aging population and expanded coverage—offer growth opportunities. Centene competes with other major managed-care firms in a sector characterized by tight reimbursement controls, compliance standards, and evolving public policy.
tl;dr
On September 11, 2025, Centene’s stock closed at $36.00, up 15.13% on heightened trading volume. First-quarter 2025 results showed a 17% increase in revenue and an adjusted EPS of $2.90, prompting a $6 billion increase in full-year revenue guidance. State contract renewals in Nevada and Illinois will begin in January 2026, supporting membership gains. The company projects full-year adjusted EPS above $7.25 and continues to deploy capital toward community-based initiatives and selective divestitures.